RPA
ELDN icon

Redwood Park Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Redwood Park Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-700
Closed -$1.81K – 328
2025
Q3 		$1.81K Buy
+700
New +$2.05K ﹤0.01% 223

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Redwood Park Advisors's ELDN Position: Q4 2025 in Review

Redwood Park Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 700 shares — an estimated $1.81K sold.

Redwood Park Advisors first reported a position in ELDN in Q3 2025 and held it in 1 quarter. The position peaked at $1.81K in Q3 2025. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Redwood Park Advisors reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Redwood Park Advisors sold 700 Eledon Pharmaceuticals shares in Q4 2025, an estimated $1.81K.
  • Redwood Park Advisors first reported a position in Eledon Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Redwood Park Advisors's Eledon Pharmaceuticals position peaked at $1.81K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Redwood Park Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.